Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

damagesstatutepatent
statutepatent

Related Cases

Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. 93, 136 S.Ct. 1923, 195 L.Ed.2d 278, 84 USLW 4386, 118 U.S.P.Q.2d 1761, 16 Cal. Daily Op. Serv. 6086, 2016 Daily Journal D.A.R. 5663, 26 Fla. L. Weekly Fed. S 246
View Case »
Manville Sales Corp. v. Paramount Systems, Inc., 917 F.2d 544, 16 U.S.P.Q.2d 1587
View Case »
Mercoid Corp. v. Minneapolis-Honeywell Regulator Co., 320 U.S. 680, 64 S.Ct. 278, 88 L.Ed. 396, 60 U.S.P.Q. 30
View Case »
In re Kollar, 286 F.3d 1326, 62 U.S.P.Q.2d 1425
View Case »
Lam, Inc. v. Johns-Manville Corp., 718 F.2d 1056, 219 U.S.P.Q. 670
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 125 S.Ct. 2372, 162 L.Ed.2d 160, 73 USLW 4468, 74 U.S.P.Q.2d 1801, 05 Cal. Daily Op. Serv. 5026, 2005 Daily Journal D.A.R. 6861, 18 Fla. L. Weekly Fed. S 394

Facts

The case involves a patent infringement dispute where the owner of patents for pharmacologically useful peptides sued a competitor, researcher, and research institute for infringement and inducement of infringement. The jury found in favor of the patent owner, leading to a damages award. The Federal Circuit affirmed in part and reversed in part, particularly regarding the applicability of the patent statute's safe harbor provision. The Supreme Court ultimately held that the safe harbor provision applies to preclinical studies of patented compounds that are reasonably related to the FDA's regulatory process.

Issue

Rule

Analysis

The court analyzed the safe harbor provision and determined that it encompasses all uses of patented inventions that are reasonably related to the development and submission of information under the FDCA. The court emphasized that the exemption is not limited to preclinical data pertaining solely to safety in humans, but also includes studies related to efficacy and other characteristics of the drug. The court found that the Federal Circuit had applied the wrong standard in determining whether the activities were protected under the safe harbor.

Conclusion

Who won?

The Supreme Court ruled in favor of Eli Lilly, determining that the use of patented compounds in preclinical studies is protected under the safe harbor provision of the patent statute. The Court found that the Federal Circuit had misinterpreted the scope of the safe harbor, which is intended to provide broad protection for research activities that are reasonably related to the FDA's regulatory process. This ruling allows for greater flexibility in the use of patented inventions in the context of drug development.

The Supreme Court ruled in favor of Eli Lilly, determining that the use of patented compounds in preclinical studies is protected under the safe harbor provision of the patent statute. The Court found that the Federal Circuit had misinterpreted the scope of the safe harbor, which is intended to provide broad protection for research activities that are reasonably related to the FDA's regulatory process.

You must be